Publication at Second Faculty of Medicine |
2004
Abstract
Current approaches of lipid lowering therapy include low fat diet and the use of wellestablished treatments. There is also the development of the novel agents which interfere with different levels of cholesterol metabolism are being developed.
Ezetimibe is the first agent of a novel class of selective cholesterol absorption inhibitors. Ezetimibe inhibits the absorption of biliary and dietary cholesterol from the small intestine without affecting the absorption of fat-soluble vitamins, triglycerides or bile acids.